Previous 10 | Next 10 |
PALO ALTO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today ...
BridgeBio Pharma (BBIO) rose 4% after it was pitched long at the virtual Sohn Investment Conference.Perceptive Advisors Ellen Hukkelhoven recommended the biotech company at the charity conference.Developing story ... For further details see: BridgeBio Pharma gains as name pitc...
BridgeBio Pharma (NASDAQ: BBIO) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We are updating our model post the 1Q21 print. We removed patidegib, after the Ph3 trial failed to hit primary and secondary endpoints. We incre...
BridgeBio Pharma (BBIO): Q1 GAAP EPS of -$1.18 misses by $0.37.Revenue of $0.46MCash, cash equivalents and marketable securities, excluding restricted cash, totaled $1,001.3 million as of March 31, 2021, compared to $607.1 million as of December 31, 2020.Press Release For further details se...
– Received U.S. Food and Drug Administration (FDA) approval for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency ( MoCD) Type A – Reported pr oof-of-...
2021 is set to be a pivotal year for BridgeBio Pharma with several catalysts across a growing pipeline of candidate genetic medicines. The company's unique R&D strategy based on partnerships with academic institutions supports the ability to regularly identify new disease targets....
Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total return of 187.1%, an active return o...
Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. From 1/2/2016 to date, investing in all 50 stocks, equally weighted, would have produced a total return of 198.2%, an active ret...
BridgeBio Pharma, Inc. (NASDAQ: BBIO) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning BridgeBio announced seven collaborations with US and Canadian academic and research institutions to take its total up to 20. It...
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic applications for patients, ...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...